Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer
Authors:
Open Access
- 28 November 2022
- Vol. 7 (6) , 100633
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- TAS-102 Safety in Metastatic Colorectal Cancer: Results From the First Postmarketing Surveillance StudyClinical Colorectal Cancer, 2016
- Renal Dysfunction Has Statistically and Clinically Significant Deleterious Effects on Anticancer Drug SafetyJournal of Clinical Oncology, 2016
- A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201)European Journal of Cancer, 2016
- TAS-102, a novel antitumor agent: A review of the mechanism of actionCancer Treatment Reviews, 2015
- Randomized Trial of TAS-102 for Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2015
- Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factorsCancer Treatment Reviews, 2013
- TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trialThe Lancet Oncology, 2012
- Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug managementCancer, 2007
- 5-Fluorouracil: mechanisms of action and clinical strategiesNature Reviews Cancer, 2003
- Hepatotoxicity of ChemotherapyThe Oncologist, 2001